Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 17 h ago

MBX Biosciences, Inc.: Paradigm Biocapital Advisors LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Paradigm Biocapital Advisors LP amended its Schedule 13G filing on MBX Biosciences, Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-128295. The filing reflects a change in the investment adviser's position in the clinical-stage biopharmaceutical company. The exact size and direction of the stake change were not disclosed in the headline. Investors should watch for further 13G or 13D filings to gauge Paradigm's conviction in MBX.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

MBX Biosciences, Inc., Paradigm Biocapital Advisors LP